Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Business
  • Education
  • Real Estate
Washingtoner

Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
Washingtoner/10175938

Trending...
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Great Junk Hunt Returns to Puyallup: The Ultimate Holiday Vintage Market is Back!
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. ("Kubota Vision"), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride ("emixustat") in patients with macular atrophy secondary to Stargardt disease.

The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 clinical study in which subjects were randomly assigned to emixustat 10 mg or placebo (2:1 ratio) once daily for 24 months. The target total number of subjects was 162; however, due to high interest in the study, a total of 194 subjects were enrolled in this study across 29 sites in 11 countries worldwide. The last patient has completed the study. The primary objective of this study is to determine if emixustat reduces the rate of macular atrophy progression, in comparison to placebo, in subjects with Stargardt disease. Secondary objectives include assessing changes in visual function parameters such as BCVA (best-corrected visual acuity) letter score and reading speed. The database of this study will be locked in the third quarter 2022.

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, "Despite Stargardt being a rare disease, we were able to enroll more patients than originally planned and feel grateful that the patients trusted our drug with great expectation and continued taking the drug for two years during the pandemic. We would like to sincerely thank all of the participants and their families for their cooperation and are very pleased that the long-term, large-scale clinical trial has been successfully completed. We are also looking forward to receiving the results of the trial in the coming months."

The FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) granted orphan drug designation to emixustat for the treatment of Stargardt disease. (See January 5, 2017 press release titled "Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease" and June 9, 2019 press release titled "Acucela Receives Orphan Designation from the EMA for Emixustat for the Treatment of Stargardt Disease")

More on Washingtoner
  • City of Spokane Responds to SREC's Mischaracterization of Fire Dispatch Delay
  • KeysCaribbean Introduces Newly Reduced Rates At Village at Hawks Cay Villas for Thanksgiving Getaways
  • Dr. Michael Leon, Chief Scientific Officer of Memory Air, Featured on Longevity Leaders Project
  • Dr. Constance Scharff Named a Fellow of The Explorers Club
  • NANNNA Shines in Stamford: The Men Who Came to Support Their Wives

About Stargardt Disease

Stargardt disease is a rare, genetically inherited disease that directly affects the retina of the eye, often resulting in the slow progression of vision loss in children. It may also be referred to as Stargardt macular dystrophy or juvenile macular degeneration and affects approximately 1 in 8,000 - 10,000 individuals worldwide.*1 The most common form of the disease is caused by a genetic mutation of the ABCA4 gene leading to the accumulation of toxic vitamin A byproducts (primarily A2E) in the retina, which results in the gradual deterioration of photoreceptors and vision. Symptoms of Stargardt disease typically appear during childhood or adolescence, but in some cases difficulty with eyesight and vision loss may not be identified until later in life.

Stargardt disease affects less than 150,000 patients in total in the U.S., Europe and Japan where it is recognized as an orphan disease. Currently, there are no known therapies that slow the advance of the disease, and it is recognized as a serious unmet medical need.

*1 Facts About Stargardt Disease, National Eye Institute. https://nei.nih.gov/health/stargardt/star_facts, accessed on 14 September 2018.

About Emixustat Hydrochloride

Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65). The visual cycle is the process by which vitamin A is recycled in the eye; vitamin A is crucial to the visual process. Slowing the visual cycle reduces the availability of vitamin A derivatives (11-cis- and all-trans-retinal) to form precursors of toxic A2E and related compounds. In addition, reducing the availability of 11-cis-retinal decreases retinal metabolic demands under dark conditions. Emixustat when delivered orally was found to be generally well tolerated in human clinical studies with delayed dark adaptation being the most common adverse event. Kubota Vision is exploring emixustat's potential to stop or slow the progression of vision loss in patients diagnosed with Stargardt disease in an ongoing clinical study.

More on Washingtoner
  • Aoolia Offers Free Virtual Try On Glasses for 1,500+ Frames Using Just a Phone Camera
  • Education Through Music-LA Honors Grammy-Winning Pitch Perfect Music Supervisors Julianne Jordan & Julia Michels, Educator Anthony "Tony" White
  • TOKSTAR Welcomes NBA 2K Star Young Wayne
  • Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements: https://www.kubotaholdings.co.jp/en/1/index.html

"Kubota Vision", the Kubota Vision logo and "Kubota" are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Contacts

Media and Investor Relations Contact:

Mikio Fukai
Corporate Planning Division
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Spokane: Local Leaders Celebrate Community Redevelopment in East Central
  • A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
  • Holiday Magic Returns to Downtown Downers Grove November 27-29
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Great Junk Hunt Returns to Puyallup: The Ultimate Holiday Vintage Market is Back!
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Coming Up on CNBC: Bilha Wachira Champions Financial Protection During Long-Term Care Awareness Month
  • Tacoma: Closures Projected to Allow for Arterial Work
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 338
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 301
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 190
  • One in three Americans may have lost track of retirement savings from a previous job - 124
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026 - 122
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network - 107
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search - 105
  • Tacoma: OMWBE Active Certification Class on November 16 - 103
  • Sturtevant's Offers Free Ski and Snowboard Edge-and-Wax Services in Bellevue Oct. 29
  • Paraguay Expedition Offers a Different View of Human Resilience

Similar on Washingtoner

  • Veteran Consulting Helps Washington Businesses Cut Operating Costs — No Upfront Fees
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute